Mesenchymal Stem Cells Comprehensive Study by Type (MSC-BM, MSC-UC, MSC-AT, Others), Application (Cell Differentiation and Gene Regulation, Gene Therapy and Transplantation, Cell-based Screening Assays, Others) Players and Region - Global Market Outlook to 2024

Mesenchymal Stem Cells Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Mesenchymal Stem Cells Market Scope
Mesenchymal stem cells help to replace or repair damaged tissue. The mesenchymal stem cells market is expected to grow in the future due to the rising aging population and an increasing number of chronic disease and bone and cartilage disease patients.

The market study is being classified by Type (MSC-BM, MSC-UC, MSC-AT and Others), by Application (Cell Differentiation and Gene Regulation, Gene Therapy and Transplantation, Cell-based Screening Assays and Others) and major geographies with country level break-up.

The global mesenchymal stem cells market is fragmented and key players in the market are introducing innovative products along with targeting partnerships and collaborations. Global players are entering new markets in developing regions to expand their customer base and strengthen market presence. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Mesenchymal Stem Cells market throughout the predicted period.

Lonza Group (Switzerland), Thermo Fisher Scientific (United States), Bio-Techne Corporation (United States), Miltenyi Biotec (Germany), PromoCell GmbH (Germany), Irvine Scientific (United States), Axol Bioscience (United Kingdom), STEMCELL Technologies Inc.(Canada), Biological Industries (Israel) and Mesoblast Limited (Australia) are some of the key players profiled in the study.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Mesenchymal Stem Cells market by Type, Application and Region.

On the basis of geography, the market of Mesenchymal Stem Cells has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In Sept 2019, A new study released in STEM CELLS demonstrates that mesenchymal stromal cells (MSCs) expanded from adipose tissue (ASC) outperform those expanded from bone marrow (BM-MSCs). Importantly, while several previous studies have compared the performance of BM-MSCs versus ASCs, this is the first to pair MSCs from the same donor to show that tissue, rather than donor origin, is the functional predictor.


Market Trend
  • Rising Innovation related to Mesenchymal Stem Cells Products

Market Drivers
  • Growing Geriatric Population
  • Rising Number of Patients of Chronic Diseases, Bone and Cartilage Diseases, and Autoimmune Diseases

Opportunities
  • Growth in Government Support ion form of Regulations and Funding
  • Developing Healthcare Infrastructure in Developing Countries

Restraints
  • Lack of Therapeutic Advancement in Underdeveloped Countries

Challenges
  • Some Adverse Effects Transplanted Mesenchymal Stem Cells


Key Target Audience
Mesenchymal Stem Cells Therapeutics, Healthcare industry, Potential Investors and Research and Development Organisation

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase

Report Objectives / Segmentation Covered

By Type
  • MSC-BM
  • MSC-UC
  • MSC-AT
  • Others
By Application
  • Cell Differentiation and Gene Regulation
  • Gene Therapy and Transplantation
  • Cell-based Screening Assays
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Geriatric Population
      • 3.2.2. Rising Number of Patients of Chronic Diseases, Bone and Cartilage Diseases, and Autoimmune Diseases
    • 3.3. Market Challenges
      • 3.3.1. Some Adverse Effects Transplanted Mesenchymal Stem Cells
    • 3.4. Market Trends
      • 3.4.1. Rising Innovation related to Mesenchymal Stem Cells Products
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Mesenchymal Stem Cells, by Type, Application and Region (value and price ) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Mesenchymal Stem Cells (Value)
      • 5.2.1. Global Mesenchymal Stem Cells by: Type (Value)
        • 5.2.1.1. MSC-BM
        • 5.2.1.2. MSC-UC
        • 5.2.1.3. MSC-AT
        • 5.2.1.4. Others
      • 5.2.2. Global Mesenchymal Stem Cells by: Application (Value)
        • 5.2.2.1. Cell Differentiation and Gene Regulation
        • 5.2.2.2. Gene Therapy and Transplantation
        • 5.2.2.3. Cell-based Screening Assays
        • 5.2.2.4. Others
      • 5.2.3. Global Mesenchymal Stem Cells Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Mesenchymal Stem Cells (Price)
      • 5.3.1. Global Mesenchymal Stem Cells by: Type (Price)
  • 6. Mesenchymal Stem Cells: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Lonza Group (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher Scientific (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bio-Techne Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Miltenyi Biotec (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. PromoCell GmbH (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Irvine Scientific (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Axol Bioscience (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. STEMCELL Technologies Inc.(Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Biological Industries (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mesoblast Limited (Australia)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Mesenchymal Stem Cells Sale, by Type, Application and Region (value and price ) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Mesenchymal Stem Cells (Value)
      • 7.2.1. Global Mesenchymal Stem Cells by: Type (Value)
        • 7.2.1.1. MSC-BM
        • 7.2.1.2. MSC-UC
        • 7.2.1.3. MSC-AT
        • 7.2.1.4. Others
      • 7.2.2. Global Mesenchymal Stem Cells by: Application (Value)
        • 7.2.2.1. Cell Differentiation and Gene Regulation
        • 7.2.2.2. Gene Therapy and Transplantation
        • 7.2.2.3. Cell-based Screening Assays
        • 7.2.2.4. Others
      • 7.2.3. Global Mesenchymal Stem Cells Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Mesenchymal Stem Cells (Price)
      • 7.3.1. Global Mesenchymal Stem Cells by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Mesenchymal Stem Cells: by Type(USD Million)
  • Table 2. Mesenchymal Stem Cells MSC-BM , by Region USD Million (2013-2018)
  • Table 3. Mesenchymal Stem Cells MSC-UC , by Region USD Million (2013-2018)
  • Table 4. Mesenchymal Stem Cells MSC-AT , by Region USD Million (2013-2018)
  • Table 5. Mesenchymal Stem Cells Others , by Region USD Million (2013-2018)
  • Table 6. Mesenchymal Stem Cells: by Application(USD Million)
  • Table 7. Mesenchymal Stem Cells Cell Differentiation and Gene Regulation , by Region USD Million (2013-2018)
  • Table 8. Mesenchymal Stem Cells Gene Therapy and Transplantation , by Region USD Million (2013-2018)
  • Table 9. Mesenchymal Stem Cells Cell-based Screening Assays , by Region USD Million (2013-2018)
  • Table 10. Mesenchymal Stem Cells Others , by Region USD Million (2013-2018)
  • Table 11. South America Mesenchymal Stem Cells, by Country USD Million (2013-2018)
  • Table 12. South America Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 13. South America Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 14. Brazil Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 15. Brazil Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 16. Argentina Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 17. Argentina Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 18. Rest of South America Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 19. Rest of South America Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 20. Asia Pacific Mesenchymal Stem Cells, by Country USD Million (2013-2018)
  • Table 21. Asia Pacific Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 22. Asia Pacific Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 23. China Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 24. China Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 25. Japan Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 26. Japan Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 27. India Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 28. India Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 29. South Korea Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 30. South Korea Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 31. Taiwan Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 32. Taiwan Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 33. Australia Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 34. Australia Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 35. Rest of Asia-Pacific Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 36. Rest of Asia-Pacific Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 37. Europe Mesenchymal Stem Cells, by Country USD Million (2013-2018)
  • Table 38. Europe Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 39. Europe Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 40. Germany Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 41. Germany Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 42. France Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 43. France Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 44. Italy Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 45. Italy Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 46. United Kingdom Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 47. United Kingdom Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 48. Netherlands Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 49. Netherlands Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 50. Rest of Europe Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 51. Rest of Europe Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 52. MEA Mesenchymal Stem Cells, by Country USD Million (2013-2018)
  • Table 53. MEA Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 54. MEA Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 55. Middle East Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 56. Middle East Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 57. Africa Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 58. Africa Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 59. North America Mesenchymal Stem Cells, by Country USD Million (2013-2018)
  • Table 60. North America Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 61. North America Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 62. United States Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 63. United States Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 64. Canada Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 65. Canada Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 66. Mexico Mesenchymal Stem Cells, by Type USD Million (2013-2018)
  • Table 67. Mexico Mesenchymal Stem Cells, by Application USD Million (2013-2018)
  • Table 68. Mesenchymal Stem Cells: by Type(USD/Units)
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Mesenchymal Stem Cells: by Type(USD Million)
  • Table 80. Mesenchymal Stem Cells MSC-BM , by Region USD Million (2019-2024)
  • Table 81. Mesenchymal Stem Cells MSC-UC , by Region USD Million (2019-2024)
  • Table 82. Mesenchymal Stem Cells MSC-AT , by Region USD Million (2019-2024)
  • Table 83. Mesenchymal Stem Cells Others , by Region USD Million (2019-2024)
  • Table 84. Mesenchymal Stem Cells: by Application(USD Million)
  • Table 85. Mesenchymal Stem Cells Cell Differentiation and Gene Regulation , by Region USD Million (2019-2024)
  • Table 86. Mesenchymal Stem Cells Gene Therapy and Transplantation , by Region USD Million (2019-2024)
  • Table 87. Mesenchymal Stem Cells Cell-based Screening Assays , by Region USD Million (2019-2024)
  • Table 88. Mesenchymal Stem Cells Others , by Region USD Million (2019-2024)
  • Table 89. South America Mesenchymal Stem Cells, by Country USD Million (2019-2024)
  • Table 90. South America Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 91. South America Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 92. Brazil Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 93. Brazil Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 94. Argentina Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 95. Argentina Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 96. Rest of South America Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 97. Rest of South America Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 98. Asia Pacific Mesenchymal Stem Cells, by Country USD Million (2019-2024)
  • Table 99. Asia Pacific Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 100. Asia Pacific Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 101. China Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 102. China Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 103. Japan Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 104. Japan Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 105. India Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 106. India Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 107. South Korea Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 108. South Korea Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 109. Taiwan Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 110. Taiwan Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 111. Australia Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 112. Australia Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 113. Rest of Asia-Pacific Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 114. Rest of Asia-Pacific Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 115. Europe Mesenchymal Stem Cells, by Country USD Million (2019-2024)
  • Table 116. Europe Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 117. Europe Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 118. Germany Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 119. Germany Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 120. France Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 121. France Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 122. Italy Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 123. Italy Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 124. United Kingdom Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 125. United Kingdom Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 126. Netherlands Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 127. Netherlands Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 128. Rest of Europe Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 129. Rest of Europe Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 130. MEA Mesenchymal Stem Cells, by Country USD Million (2019-2024)
  • Table 131. MEA Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 132. MEA Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 133. Middle East Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 134. Middle East Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 135. Africa Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 136. Africa Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 137. North America Mesenchymal Stem Cells, by Country USD Million (2019-2024)
  • Table 138. North America Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 139. North America Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 140. United States Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 141. United States Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 142. Canada Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 143. Canada Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 144. Mexico Mesenchymal Stem Cells, by Type USD Million (2019-2024)
  • Table 145. Mexico Mesenchymal Stem Cells, by Application USD Million (2019-2024)
  • Table 146. Mesenchymal Stem Cells: by Type(USD/Units)
  • Table 147. Research Programs/Design for This Report
  • Table 148. Key Data Information from Secondary Sources
  • Table 149. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Mesenchymal Stem Cells: by Type USD Million (2013-2018)
  • Figure 5. Global Mesenchymal Stem Cells: by Application USD Million (2013-2018)
  • Figure 6. South America Mesenchymal Stem Cells Share (%), by Country
  • Figure 7. Asia Pacific Mesenchymal Stem Cells Share (%), by Country
  • Figure 8. Europe Mesenchymal Stem Cells Share (%), by Country
  • Figure 9. MEA Mesenchymal Stem Cells Share (%), by Country
  • Figure 10. North America Mesenchymal Stem Cells Share (%), by Country
  • Figure 11. Global Mesenchymal Stem Cells: by Type USD/Units (2013-2018)
  • Figure 12. Global Mesenchymal Stem Cells share by Players 2018 (%)
  • Figure 13. Global Mesenchymal Stem Cells share by Players (Top 3) 2018(%)
  • Figure 14. Global Mesenchymal Stem Cells share by Players (Top 5) 2018(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Lonza Group (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. Lonza Group (Switzerland) Revenue: by Geography 2018
  • Figure 18. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 19. Thermo Fisher Scientific (United States) Revenue: by Geography 2018
  • Figure 20. Bio-Techne Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 21. Bio-Techne Corporation (United States) Revenue: by Geography 2018
  • Figure 22. Miltenyi Biotec (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Miltenyi Biotec (Germany) Revenue: by Geography 2018
  • Figure 24. PromoCell GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 25. PromoCell GmbH (Germany) Revenue: by Geography 2018
  • Figure 26. Irvine Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 27. Irvine Scientific (United States) Revenue: by Geography 2018
  • Figure 28. Axol Bioscience (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. Axol Bioscience (United Kingdom) Revenue: by Geography 2018
  • Figure 30. STEMCELL Technologies Inc.(Canada) Revenue, Net Income and Gross profit
  • Figure 31. STEMCELL Technologies Inc.(Canada) Revenue: by Geography 2018
  • Figure 32. Biological Industries (Israel) Revenue, Net Income and Gross profit
  • Figure 33. Biological Industries (Israel) Revenue: by Geography 2018
  • Figure 34. Mesoblast Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 35. Mesoblast Limited (Australia) Revenue: by Geography 2018
  • Figure 36. Global Mesenchymal Stem Cells: by Type USD Million (2019-2024)
  • Figure 37. Global Mesenchymal Stem Cells: by Application USD Million (2019-2024)
  • Figure 38. South America Mesenchymal Stem Cells Share (%), by Country
  • Figure 39. Asia Pacific Mesenchymal Stem Cells Share (%), by Country
  • Figure 40. Europe Mesenchymal Stem Cells Share (%), by Country
  • Figure 41. MEA Mesenchymal Stem Cells Share (%), by Country
  • Figure 42. North America Mesenchymal Stem Cells Share (%), by Country
  • Figure 43. Global Mesenchymal Stem Cells: by Type USD/Units (2019-2024)
List of companies from research coverage that are profiled in the study
  • Lonza Group (Switzerland)
  • Thermo Fisher Scientific (United States)
  • Bio-Techne Corporation (United States)
  • Miltenyi Biotec (Germany)
  • PromoCell GmbH (Germany)
  • Irvine Scientific (United States)
  • Axol Bioscience (United Kingdom)
  • STEMCELL Technologies Inc.(Canada)
  • Biological Industries (Israel)
  • Mesoblast Limited (Australia)
Select User Access Type

Key Highlights of Report


Jan 2020 202 Pages 91 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Mesenchymal Stem Cells Report?